Successful therapeutic response of resistant cases of mucocutaneous leishmaniasis to a very low dose of antimony.
Two mucocutaneous leishmaniasis cases resistant to therapy are reported here. After the failure of initial therapies (antimony, amphotericin B and/or pentamidine) patients received a low-dose schedule: one ampoule of meglumine antimoniate (405 mg of pentavalent antimony [Sb v]) by intramuscular injection, three times a week until complete healing of the lesions. One patient was cured with a total of 30 ampoules in 10 weeks and the other received 36 ampoules in 12 weeks. Both remain clinically cured after one year of follow-up.
de Oliveira-Neto
Manoel Paes
MP
Instituto de Pesquisas Clínicas Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, RJ.
Mattos
Marise da Silva
Mda S
D000328:Adult; D000981:Antiprotozoal Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004427:Ear Diseases / Q000188:drug therapy; D004431:Ear, External; D005500:Follow-Up Studies; D006801:Humans; D007273:Injections, Intramuscular; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy*; D008297:Male; D008536:Meglumine / Q000008:administration & dosage*; D000077485:Meglumine Antimoniate; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage*; D010409:Penile Diseases / Q000188:drug therapy; D016896:Treatment Outcome
D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate